Viruses, immunity, and cancer: Lessons from hepatitis B

American Journal of Pathology

Volumn 156, Issue 4, 2000, Pages 1117-1132

  Chisari, F V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ANIMAL MODEL; CHRONIC HEPATITIS; CYTOTOXIC T LYMPHOCYTE; HEPATITIS B VIRUS; LIVER CELL CARCINOMA; LIVER DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; VIRUS GENOME; VIRUS HEPATITIS; VIRUS REPLICATION; ANIMAL; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOLOGY; LIVER TUMOR; PAN TROGLODYTES; PHYSIOLOGY; VIROLOGY;

ANIMALS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNITY; LIVER NEOPLASMS; PAN TROGLODYTES;

EID: 0034167525     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9440(10)64980-2     Document Type: Review

References (108)

1. Transmission of type B viral hepatitis to chimpanzees
2. Hepatitis B virus immunopathogenesis
3. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan
4. Hepatitis B virus biology and pathogenesis
5. Hepatitis B virus structure and biology
6. Significance of the immune response to a major, conformational B cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody
7. A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins
8. Transferrin receptor mediates uptake and presentation of hepatitis B envelope antigen by T lymphocytes
9. Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus envelope protein
10. Hepatitis B virus surface antigen binds to apolipoprotein H
11. Carboxypeptidase D is an avian hepatitis B virus receptor
12. Identification of a membrane-bound carboxypeptidase as the mammalian homolog of duck gp180, a hepatitis B virus-binding protein
13. Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice
14. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
15. The molecular biology of the hepatitis B viruses
16. Assembly of viral particles in Xenopus oocytes: Pre-surface-antigens regulate secretion of the hepatitis B viral surface envelope particle
17. High level hepatitis B virus replication in transgenic mice
18. Asymmetric replication of duck hepatitis B virus DNA in liver cells (free minus-strand DNA)
19. Hepatitis B viral DNA-RNA hybrid molecules in particles from infected liver are converted to viral DNA molecules during an endogenous DNA polymerase reaction
20. Mapping of the cohesive overlap of duck hepatitis B virus DNA and of the site of initiation of reverse transcription
21. Biochemical and genetic evidence for the hepatitis B virus replication strategy
22. Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis
23. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
24. Replication strategy of human hepatitis B virus
25. Hepadnaviruses and retroviruses share genome homology and features of replication
26. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?
27. Characterization of self-reactive T cells that evade tolerance in hepatitis B e antigen transgenic mice
28. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice
29. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis
30. Posttranscriptional regulation of hepatitis B virus replication by the precore protein
31. Cytoplasmic hepatitis B antigen in 'ground-glass' hepatocytes of carriers
32. Mechanisms of class I restricted immunopathology: A transgenic mouse model of fulminant hepatitis
33. Hepatitis B virus X gene product acts as a transactivator in vivo
34. Woodchuck hepatitis virus X protein is required for viral infection in vivo
35. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
36. Hepatitis B virus persistence after recovery from acute viral hepatitis
37. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response
38. Persistence of memory CD8 T cells in MHC class I-deficient mice
39. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice
40. Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice
41. Peroxidase-antiperoxidase detection of hepatitis B surface and core antigen in liver biopsy specimens from patients with chronic type B hepatitis
42. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection
43. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state
44. Class I restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo
45. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice
46. + immune T cells against toxoplasmosis in mice
47. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
48. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver
49. Cytotoxic T lymohocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
50. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in HBV envelope transgenic mice
51. Post-transcriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes
52. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice
53. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA
54. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice
55. Interleukin-12 inhibits hepatitis B virus replication in HBV transgenic mice
56. Tumor necrosis factor-alpha negatively regulates hepatitis B virus gene expression in transgenic mice
57. Interleukin 2 and interferon alpha/beta downregulate hepatitis B virus gene expression in vivo by tumor necrosis factor dependent and independent pathways
58. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a post-transcriptional mechanism
59. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in HBV transgenic mice
60. Acute type A hepatitis during chronic hepatitis B virus infection: Association of depressed hepatitis B virus replication with appearance of endogenous alpha interferon
61. Role of hepatitis C and delta viruses n the termination of chronic hepatitis B surface antigen carrier state: A multivariate analysis in a longitudinal follow-up study
62. Human class I supertypes and CTL repertoires extend to chimpanzees
63. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte
64. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen
65. HLA-A31- and HLA-Aw68 restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis
66. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection
67. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
68. Fas ligand-induced apoptosis as a mechanism of immune privilege
69. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
70. Virus proteins that counteract host immune defenses
71. Cytokine receptors encoded by poxviruses: A lesson in cytokine biology
72. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen
73. Hepatitis B virus (HBV) sequence variation in cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection
74. Natural variants of cytotoxic epitopes are T cell receptor antagonists for antiviral cytotoxic T cells
75. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire
76. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus
77. A single TCR antagonist peptide inhibits experimental allergic encelphalomyelitis by a diverse T cell repertoire
78. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
79. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
80. Hepatitis C virus (HCV)-specific cytoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
81. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
82. + cells with a predominant V-beta usage during the primary immune response to HIV
83. Variability of hepatitis C virus
84. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis
85. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
86. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis
87. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions
88. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway
89. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX
90. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and associated with transcription factor ERCC3
91. High level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
92. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator
93. Hepatitis B virus transactivator MHBst: Activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization
94. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice
95. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice
96. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
97. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice
98. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice
99. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma
100. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice
101. Immune pathogenesis of hepatocellular carcinoma
102. Transfusion-associated non-A, non-B hepatitis: The first decade
103. Alcohol and cancer
104. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis
105. Hepatocellular carcinoma in type 1 glycogen storage disease
106. Chronic 'cryptogenic' liver disease and malignant hepatoma in intermediate alpha-1-antitrypsin deficiency identified by a pi 2-specific monoclonal antibody
107. Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency
108. Hepatocellular carcinoma in the non-cirrhotic liver: A comparison with that complicating cirrhosis